Barclays PLC Biogen Inc. Put Options Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Put Options

23 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$189.07 - $236.8 $5.82 Million - $7.29 Million
30,800 New
30,800 $5.97 Million
Q1 2024

May 15, 2024
BUY
$212.02 - $267.71 $3.18 Million - $4.02 Million
15,000 Added 58.14%
40,800 $8.8 Million
Q4 2023

Feb 15, 2024
BUY
$222.59 - $267.94 $4.05 Million - $4.88 Million
18,200 Added 239.47%
25,800 $6.68 Million
Q3 2023

Nov 07, 2023
SELL
$253.3 - $285.89 $12.7 Million - $14.4 Million
-50,200 Reduced 86.85%
7,600 $1.95 Million
Q2 2023

Aug 03, 2023
BUY
$275.25 - $318.06 $10 Million - $11.6 Million
36,400 Added 170.09%
57,800 $16.5 Million
Q1 2023

May 04, 2023
SELL
$256.56 - $292.34 $25.4 Million - $29 Million
-99,100 Reduced 82.24%
21,400 $5.95 Million
Q4 2022

Feb 13, 2023
BUY
$252.44 - $306.72 $30.4 Million - $37 Million
120,500 New
120,500 $33.4 Million
Q2 2022

Aug 12, 2022
BUY
$187.54 - $223.02 $10.9 Million - $12.9 Million
58,000 Added 68.64%
142,500 $29.1 Million
Q4 2021

Feb 14, 2022
SELL
$223.92 - $287.77 $806,112 - $1.04 Million
-3,600 Reduced 4.09%
84,500 $20.3 Million
Q4 2020

Feb 11, 2021
BUY
$236.26 - $355.63 $6.21 Million - $9.35 Million
26,300 Added 42.56%
88,100 $21.6 Million
Q3 2020

Nov 12, 2020
SELL
$264.77 - $305.71 $370,678 - $427,994
-1,400 Reduced 2.22%
61,800 $17.5 Million
Q2 2020

Aug 12, 2020
SELL
$258.66 - $342.55 $15.1 Million - $20 Million
-58,500 Reduced 48.07%
63,200 $16.9 Million
Q1 2020

May 13, 2020
SELL
$268.85 - $341.04 $20.4 Million - $25.9 Million
-75,800 Reduced 38.38%
121,700 $38.5 Million
Q4 2019

Feb 10, 2020
BUY
$220.06 - $304.07 $2.29 Million - $3.16 Million
10,400 Added 5.56%
197,500 $58.6 Million
Q3 2019

Nov 14, 2019
BUY
$217.44 - $243.88 $5.28 Million - $5.93 Million
24,300 Added 14.93%
187,100 $43.6 Million
Q2 2019

Aug 14, 2019
BUY
$219.29 - $241.72 $13.8 Million - $15.2 Million
63,000 Added 63.13%
162,800 $38.1 Million
Q1 2019

May 15, 2019
SELL
$216.71 - $338.96 $25.3 Million - $39.5 Million
-116,600 Reduced 53.88%
99,800 $23.6 Million
Q4 2018

Feb 14, 2019
SELL
$278.5 - $352.75 $12.4 Million - $15.7 Million
-44,600 Reduced 17.09%
216,400 $65.1 Million
Q3 2018

Nov 14, 2018
BUY
$293.51 - $383.83 $19.5 Million - $25.5 Million
66,400 Added 34.12%
261,000 $92.2 Million
Q2 2018

Aug 14, 2018
BUY
$257.52 - $306.91 $3.61 Million - $4.3 Million
14,000 Added 7.75%
194,600 $56.5 Million
Q1 2018

May 15, 2018
SELL
$260.13 - $367.91 $7.13 Million - $10.1 Million
-27,400 Reduced 13.17%
180,600 $49.5 Million
Q4 2017

Feb 14, 2018
SELL
$307.64 - $344.58 $10.2 Million - $11.4 Million
-33,100 Reduced 13.73%
208,000 $66.3 Million
Q3 2017

Nov 14, 2017
BUY
$281.15 - $329.69 $67.8 Million - $79.5 Million
241,100
241,100 $75.5 Million

Others Institutions Holding BIIB

# of Institutions
1,037
Shares Held
126M
Call Options Held
1.13M
Put Options Held
1.43M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email